Affiliation:
1. Clinical Assistant Professor of Anesthesiology and Pain Management Department of Anesthesiology and Pain Management Children's Health System Texas Dallas Texas USA
2. Professor, Anesthesiology, Perioperative and Pain Medicine, and Pediatrics Stanford University Stanford California USA
3. Department of Anesthesiology Division of Pediatric Anesthesiology The University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA
4. Department of Critical Care and Anesthesia National Center for Child Health and Development Tokyo Japan
5. Post Approval Clinical Development Pfizer, Inc. New York New York USA
Abstract
AbstractBackgroundDexmedetomidine is a selective α2‐adrenergic agonist originally approved for sedation of adults in the intensive care unit and subsequently approved for procedural sedation in adults undergoing medical procedures. Dexmedetomidine is widely used off‐label for procedural sedation in children.AimsTo evaluate efficacy and safety of monotherapy dexmedetomidine for magnetic resonance imaging procedural sedation of children ≥1month–<17years across three ascending doses.MethodsRandomized, double‐blind, dose‐ranging study of procedural sedation recruited patients at USA and Japanese sites from February 2020 to November 2021. Patients were stratified into Cohort A (≥1month–<2years) or Cohort B (≥2–<17years). Cohort A loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.0 mcg/kg/1.0 mcg/kg/h, and 1.5 mcg/kg/1.5 mcg/kg/h. Cohort B loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.2 mcg/kg/1.0 mcg/kg/h, and 2.0 mcg/kg/1.5 mcg/kg/h. Primary endpoint was percentage of overall patients completing MRI without rescue propofol at the high versus low dose. Key secondary endpoint was percentage in each age cohort who did not require propofol at the high versus low dose.ResultsOne hundred twenty‐two patients received high‐ (n = 38), middle‐ (n = 42), or low‐dose (n = 42) dexmedetomidine. A greater percentage completed MRI without propofol rescue, while receiving high‐ versus low‐dose dexmedetomidine (24/38 [63.2%] vs. 6/42 [14.3%]) (odds ratio: 10.29, 95% confidence interval: 3.47–30.50, p < .001). Similar results were seen in both age cohorts. The most common adverse events were bradypnea, bradycardia, hypertension, and hypotension, and the majority were of mild‐to‐moderate severity.ConclusionsDexmedetomidine was well tolerated. The high dose was associated with meaningfully greater efficacy compared with lower doses. Based on these results, the recommended starting dose for procedural sedation in children ≥1month–<2years is loading dose 1.5 mcg/kg/maintenance infusion 1.5 mcg/kg/h; children ≥2–<17years is loading dose 2.0 mcg/kg/maintenance infusion 1.5 mcg/kg/h.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献